Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Explore our online Annual Report 2024 summary Discover how we champion inclusion and diversity at AstraZeneca We have 191 projects in our pipeline View pipeline Learn about our cell therapy ambition ...
AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 2021.More than 100 abstracts will feature ...
Learn more about past programs. Annual Reports 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Special Report Helping to Improve Heart Health: Reflections from a 10-Year Journey Latest AstraZeneca Foundation News Latest Search Clear search More filters Less filters Filters Appl...
According to a GlobalData report, the NSCLC market, valued at $30.7bn in 2021, is set to grow to $45.4bn by 2031. The space is dominated by Keytruda (pembrolizumab), marketed by MSD, and AstraZeneca’s own Tagrisso (osimertinib mesylate), which are predicted to generate $28.6bn and $6....
AstraZeneca Annual Report 2023. Available at:https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2023/pdf/AstraZeneca_AR_2023.pdf. [Last accessed:April 2024]. AstraZeneca plc. FY and Q4 2023 Results. Conference call and webcast for investors and analysts. Availabl...
How much do people at Astrazeneca PLC get paid? See the latest salaries by department and job title. The average estimated annual salary, including base and bonus, at Astrazeneca PLC is $130,004, or $62 per hour, while the estimated median salary is $128,333, or $61 per hour. ...
ASTRAZENECA PLC Add to a listPDF Report AstraZeneca PLC Stock Equities AZN GB0009895292 Pharmaceuticals Real-time Estimate Cboe Europe 05:00:54 2025-02-20 am EST 5-day change 1st Jan Change 11,502.00 GBX -0.29% -3.81% +9.94% 04:06am FTSE 100 underperforms but Centrica jumps AN ...
Economic, competitive, governmental, technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion's Annual ...
AstraZeneca will share updates from the Company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. Five presentations will unveil the next-generatio...
The Sickle Cell Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates ...